+

WO2000068399A3 - Diffusion de sequences de transposon integratreur par des vecteurs - Google Patents

Diffusion de sequences de transposon integratreur par des vecteurs Download PDF

Info

Publication number
WO2000068399A3
WO2000068399A3 PCT/US2000/012827 US0012827W WO0068399A3 WO 2000068399 A3 WO2000068399 A3 WO 2000068399A3 US 0012827 W US0012827 W US 0012827W WO 0068399 A3 WO0068399 A3 WO 0068399A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector
integrating
mediated delivery
transposon sequences
transposase
Prior art date
Application number
PCT/US2000/012827
Other languages
English (en)
Other versions
WO2000068399A2 (fr
Inventor
R Scott Mcivor
Perry B Hackett
Estuardo Aguilar-Cordova
Original Assignee
Univ Minnesota
Baylor College Medicine
R Scott Mcivor
Perry B Hackett
Aguilar Cordova Estuardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Baylor College Medicine, R Scott Mcivor, Perry B Hackett, Aguilar Cordova Estuardo filed Critical Univ Minnesota
Priority to AU47110/00A priority Critical patent/AU4711000A/en
Priority to CA002373121A priority patent/CA2373121A1/fr
Priority to JP2000616365A priority patent/JP2002543792A/ja
Publication of WO2000068399A2 publication Critical patent/WO2000068399A2/fr
Publication of WO2000068399A3 publication Critical patent/WO2000068399A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des vecteurs non intégrateurs, de préférence des vecteurs viraux non intégrateurs, qui incluent un transposon, de préférence un transposon et des séquences nucléotidiques codant un transposon, ou mieux, un transposon, des séquences nucléotidiques codant un transposon et des séquences nucléotidiques codant un polypeptide, lequel régule l'expression de la transposase. L'invention concerne en outre des méthode d'utilisation desdits vecteurs non intégrateurs.
PCT/US2000/012827 1999-05-11 2000-05-11 Diffusion de sequences de transposon integratreur par des vecteurs WO2000068399A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU47110/00A AU4711000A (en) 1999-05-11 2000-05-11 Vector-mediated delivery of integrating transposon sequences
CA002373121A CA2373121A1 (fr) 1999-05-11 2000-05-11 Diffusion de sequences de transposon integratreur par des vecteurs
JP2000616365A JP2002543792A (ja) 1999-05-11 2000-05-11 ベクターによるトランスポゾン配列の供給及び組込み

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13356999P 1999-05-11 1999-05-11
US60/133,569 1999-05-11

Publications (2)

Publication Number Publication Date
WO2000068399A2 WO2000068399A2 (fr) 2000-11-16
WO2000068399A3 true WO2000068399A3 (fr) 2001-01-25

Family

ID=22459260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012827 WO2000068399A2 (fr) 1999-05-11 2000-05-11 Diffusion de sequences de transposon integratreur par des vecteurs

Country Status (4)

Country Link
JP (1) JP2002543792A (fr)
AU (1) AU4711000A (fr)
CA (1) CA2373121A1 (fr)
WO (1) WO2000068399A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000076157A (ko) 1997-03-11 2000-12-26 리전츠 오브 더 유니버스티 오브 미네소타 세포의 디엔에이로 핵산을 도입하는 디엔에이-기초 전이인자 시스템
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
WO2003089618A2 (fr) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Systeme de transposons, et procedes d'utilisation
WO2005062881A2 (fr) * 2003-12-24 2005-07-14 Transgenrx, Inc. Therapie genique faisant intervenir des vecteurs de transposon
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
CA2692501C (fr) * 2007-07-04 2017-10-10 Max-Delbrueck-Centrum Fuer Molekulare Medizin Variantes hyperactives de la proteine transposase du systeme de transposon sleeping beauty
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
CN105481984B (zh) * 2015-12-03 2020-09-22 上海细胞治疗研究院 一种高效介导外源基因整合的转座酶及其用途
GB201705927D0 (en) * 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
US20210285009A1 (en) * 2018-07-13 2021-09-16 The Regents Of The University Of California Retrotransposon-based delivery vehicle and methods of use thereof
CN110734929B (zh) * 2019-11-14 2022-11-22 南通大学 一种转座子介导的高效非病毒真核细胞稳定转染方法
US20250051735A1 (en) 2021-12-22 2025-02-13 Vanderbilt University Next generation transpososomes
WO2025002240A1 (fr) * 2023-06-29 2025-01-02 The University Of Hong Kong Procédé pour la transcription régulée dans le foie ou en présence d'un cancer hépatique

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485701A1 (fr) * 1990-09-28 1992-05-20 American Cyanamid Company Insertion d'ADN au moyen de transposones modifiés
WO1996001313A1 (fr) * 1994-07-01 1996-01-18 Hermann Bujard Modulateurs de transcription regules par la tetracycline
WO1996040892A1 (fr) * 1995-06-07 1996-12-19 Basf Ag Modulateurs de transcription regules par la tetracycline et presentant des specificites de fixation de l'adn modifiees
EP0756007A2 (fr) * 1995-06-30 1997-01-29 Ajinomoto Co., Ltd. Methode d'amplification d'un gene utilisant un transposon artificiel
WO1997015679A1 (fr) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Virus recombines contenant des elements genetiques mobiles et procedes d'utilisation desdits virus en therapie genique
WO1997029202A1 (fr) * 1996-02-09 1997-08-14 Het Nederlands Kanker Instituut Vecteurs et methodes afferentes permettant d'apporter a des cellules des acides nucleiques supplementaires s'integrant dans leur genome
WO1998040510A1 (fr) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Systeme transposon a base d'adn permettant d'introduire de l'acide nucleique dans l'adn d'une cellule
WO1999025817A2 (fr) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Systeme de transposon a base d'adn permettant d'introduire un acide nucleique dans l'adn d'une cellule

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485701A1 (fr) * 1990-09-28 1992-05-20 American Cyanamid Company Insertion d'ADN au moyen de transposones modifiés
WO1996001313A1 (fr) * 1994-07-01 1996-01-18 Hermann Bujard Modulateurs de transcription regules par la tetracycline
WO1996040892A1 (fr) * 1995-06-07 1996-12-19 Basf Ag Modulateurs de transcription regules par la tetracycline et presentant des specificites de fixation de l'adn modifiees
EP0756007A2 (fr) * 1995-06-30 1997-01-29 Ajinomoto Co., Ltd. Methode d'amplification d'un gene utilisant un transposon artificiel
WO1997015679A1 (fr) * 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Virus recombines contenant des elements genetiques mobiles et procedes d'utilisation desdits virus en therapie genique
WO1997029202A1 (fr) * 1996-02-09 1997-08-14 Het Nederlands Kanker Instituut Vecteurs et methodes afferentes permettant d'apporter a des cellules des acides nucleiques supplementaires s'integrant dans leur genome
WO1998040510A1 (fr) * 1997-03-11 1998-09-17 Regents Of The University Of Minnesota Systeme transposon a base d'adn permettant d'introduire de l'acide nucleique dans l'adn d'une cellule
WO1999025817A2 (fr) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Systeme de transposon a base d'adn permettant d'introduire un acide nucleique dans l'adn d'une cellule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IVICS Z ET AL: "MOLECULAR RECONSTRUCTION OF SLEEPING BEATUY A TC1-LIKE TRANSPOSON FROM FISH, AND ITS TRANSPOSITION IN HUMAN CELLS", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 91, November 1997 (1997-11-01), pages 501 - 510, XP000700195, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
CA2373121A1 (fr) 2000-11-16
AU4711000A (en) 2000-11-21
JP2002543792A (ja) 2002-12-24
WO2000068399A2 (fr) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000068399A3 (fr) Diffusion de sequences de transposon integratreur par des vecteurs
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
AU6020598A (en) Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
WO2003048202A3 (fr) Gène activant le facteur nucléaire kappa b
WO1997038010A3 (fr) Liposomes entrainant une fusion
WO2001044284A3 (fr) Peptides natriuretiques chimeres
WO2001075067A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
WO2002072616A3 (fr) Complexes de transfection
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2003070751A3 (fr) Mimetiques peptidiques partiels et procedes associes
GB2368846B (en) Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
WO2001004331A3 (fr) Amelioration de l'expression de proteines
AU2001286302A1 (en) High efficiency retroviral vector which contains genetically engineered cellularnon-coding sequence harboring splicing acceptor
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides
EP1082126A4 (fr) Nouveaux peptides
WO2002068673A3 (fr) Hin-1, gene suppresseur de tumeur
WO2001000667A3 (fr) Nouveau peptide anti-thrombine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2373121

Country of ref document: CA

Ref country code: CA

Ref document number: 2373121

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616365

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载